KR20170070978A - Stent having drug release and heat treatment functions and electromagnetic field-driven treatment system using the same - Google Patents

Stent having drug release and heat treatment functions and electromagnetic field-driven treatment system using the same Download PDF

Info

Publication number
KR20170070978A
KR20170070978A KR1020150178750A KR20150178750A KR20170070978A KR 20170070978 A KR20170070978 A KR 20170070978A KR 1020150178750 A KR1020150178750 A KR 1020150178750A KR 20150178750 A KR20150178750 A KR 20150178750A KR 20170070978 A KR20170070978 A KR 20170070978A
Authority
KR
South Korea
Prior art keywords
nanoparticles
exothermic
drug particles
stent
concentration
Prior art date
Application number
KR1020150178750A
Other languages
Korean (ko)
Other versions
KR101777194B1 (en
Inventor
박찬희
김철생
유창호
김성훈
이정호
정우석
Original Assignee
전북대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 전북대학교산학협력단 filed Critical 전북대학교산학협력단
Priority to KR1020150178750A priority Critical patent/KR101777194B1/en
Publication of KR20170070978A publication Critical patent/KR20170070978A/en
Application granted granted Critical
Publication of KR101777194B1 publication Critical patent/KR101777194B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a stent having a drug releasing and heat treatment function and an extracorporeal electromagnetic field-driven therapeutic system using the stent. More particularly, the present invention relates to a stent having a drug releasing and heat- A stent having a drug release and heat treatment function, and an extracorporeal electromagnetic field driven therapeutic system using the stent.
A stent having a drug release and heat treatment function of the present invention comprises: a body part made of a wire; Wherein the nanoparticles are formed by coating nanofibers on the body, wherein the nanoparticles and the drug particles are connected to the membrane.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a stent having a drug release and heat treatment function and an in vitro electromagnetic field drive type therapeutic system using the stent.

The present invention relates to a stent having a drug releasing and heat treatment function and an extracorporeal electromagnetic field-driven therapeutic system using the stent. More particularly, the present invention relates to a stent having a drug releasing and heat- A stent having a drug release and heat treatment function, and an extracorporeal electromagnetic field driven therapeutic system using the stent.

Many scientists and researchers are working hard to conquer cancer worldwide.

Cancer, unlike normal cells, grows at a rate that is abnormally high, affects normal cells, and even if cancer is treated, recurrence or cancer is transferred.

In addition, since cancer cells as well as cancer cells are damaged during cancer treatment, it is difficult to proceed with the treatment.

For these reasons, the number of deaths from cancer is increasing every year.

Kinds also make death in various forms, and cancer deaths are increasing every year.

Therefore, the development of a drug delivery system or a diagnostic material capable of more effective cancer treatment and diagnosis is urgently needed.

As a method of treating cancer, drug therapy and thermotherapy are representative. In the past, there has been a limit in which medicines and therapies can not be combined with each other.

Patent Document 10-2014-0136638

Disclosure of the Invention The present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide a stent having a drug release and heat treatment function capable of simultaneously treating cancer cells existing in the body by heat treatment and drug treatment, An object of the present invention is to provide an electromagnetic field driven therapeutic system.

According to an aspect of the present invention, there is provided a stent having a drug release and heat treatment function, including: a body made of wires; Wherein the nanoparticles are formed by coating nanofibers on the body, wherein the nanoparticles and the drug particles are connected to the membrane.

The exothermic nanoparticles are heated by a magnetic field.

The heat generating nanoparticles include iron oxide nanoparticles.

The heat generating nanoparticles include iron oxide nanoparticles; And a coating layer coated on the surface of the iron oxide nanoparticles, wherein the coating layer is bonded to the membrane by a first catecholizer.

The exothermic nanoparticles are moved by a magnetic field applied from the outside.

The drug particles are bound to the coating layer by a second catecholizing agent.

Wherein the drug particle is released to the lesion only at a predetermined specific PH concentration, wherein a second PH concentration at which the drug particle is separated from the second catecholator is higher than a first PH concentration at which the exothermic nanoparticles are separated from the first catecholer After the heat-generating nanoparticles are firstly separated from the membrane under a first PH concentration, the drug particles are secondarily separated from the heat-generating nanoparticles and released to the lesion under a lower second PH concentration.

Further, the extracorporeal field-excited therapeutic system of the present invention comprises: a stent inserted into a body; And a magnetic field generator disposed outside the body and generating a magnetic field, wherein the stent comprises: a body portion made of a wire; And a membrane in which nanofibers are coated on the body portion, wherein the membrane is connected to the heat generating nanoparticles and the drug particles, and the heat generating nanoparticles are heated by the magnetic field generated by the magnetic field generator .

The heat generating nanoparticles include iron oxide nanoparticles.

Wherein the exothermic nanoparticles are bound to the membrane by a first catechol, the drug particles are bound to the exothermic nanoparticles by a second catechol, and when the exothermic nanoparticles are separated from the first catecholizer, The exothermic nanoparticles are transferred to the affected part together with the drug particles.

The exothermic nanoparticles are moved together with the drug particles by a magnetic field applied from the outside.

Wherein the drug particle is released to the lesion only at a predetermined specific PH concentration, wherein a second PH concentration at which the drug particle is separated from the second catecholator is higher than a first PH concentration at which the exothermic nanoparticles are separated from the first catecholer After the heat-generating nanoparticles are firstly separated from the membrane under a first PH concentration, the drug particles are secondarily separated from the heat-generating nanoparticles and released to the lesion under a lower second PH concentration.

As described above, the stent having the drug releasing and heat treatment function of the present invention and the extracorporeal electromagnetic field driven therapeutic system using the stent have the following effects.

As described above, since the present invention is noninvasive, the stent-based heat treatment and the drug treatment can be performed simultaneously in vitro, resulting in a synergistic effect of cancer treatment.

In addition, since only the cancer cells targeted at a specific PH concentration are traced to release the drug, the cancer treatment can be accurately performed.

In addition, since the movement of the exothermic nanoparticles present in the body can be controlled by using the local magnetic field generated by the magnetic field generator, it is possible to realize a nano robot that targets and kills cancer cells while maintaining normal cells.

1 is a perspective view of a stent according to an embodiment of the present invention,
2 is a partial enlarged view of a stent according to an embodiment of the present invention,
FIG. 3 is a configuration diagram of an extracorporeal field driven type treatment system according to an embodiment of the present invention,
FIG. 4 to FIG. 6 are diagrams illustrating a process of drug release by the extracorporeal field-driven therapeutic system according to an embodiment of the present invention.

FIG. 1 is a perspective view of a stent according to an embodiment of the present invention, and FIG. 2 is a partial enlarged view of a stent according to an embodiment of the present invention.

1 and 2, a stent 10 having a drug release and heat treatment function according to the present invention comprises a body part 11 and a membrane 12.

The body portion 11 is formed by intertwining a plurality of wires, and the body portion 11 may be formed using a conventional known structure, and a detailed description thereof will be omitted.

The membrane 12 is formed of nanofibers and is coated on the surface of the body part 11.

At this time, it is preferable that a plurality of needles are protruded from the membrane 12.

The heating nanoparticles 13 and the drug particles 16 are connected to the membrane 12.

The exothermic nanoparticles 13 are preferably made of iron oxide nanoparticles 14 because they have a characteristic of generating heat by a magnetic field.

The coating layer 15 is coated on the surface of the iron oxide nano-particles 14.

The coating layer 15 is a copolymer obtained by polymerizing a 2-hydroxyethyl methacrylate monomer and a dopamine methacrylamide monomer.

Here, 2-hydroxyethyl methacrylate (HEMA) is sensitive to light and moisture, and the monomer is hydrophilic.

Dopaminemethacrylamide (DMA) also has the properties of 3,4-dihydroxyphenylalanine (3,4-dihydroxyphenylalanine, Dopa).

The 3,4-dihydroxyphenylalanine can strongly interact with the metal oxide and the surface characteristics of the various materials having polydopamine can be greatly changed by simple immersion, And may enable interaction with metal oxides.

The heating nanoparticles 13 are bonded to the membrane 12 by the first catechol 17.

That is, the first cateater 17 is formed on the surface of the coating layer 15 and is connected to the membrane 12.

Catechol mimics the attachment material of mussels and is used as a good (metal) reducing material, and the coating layer 15 can be connected to the membrane 12 using this characteristic.

This allows the membrane 12 to uniformly bind the exothermic nanoparticles 13.

As the first catheter 17 is severed, the exothermic nanoparticles 13 can freely move from the membrane 12.

At this time, the exothermic nanoparticles 13 are moved and rotated by a magnetic field applied from the outside.

The drug particles 16 are made of an anti-cancer substance or the like and are connected to the membrane 12.

The drug particles 16 may be directly connected to the membrane 12 or may be connected to the membrane 12 through the heat generating nanoparticles 13 as in the present embodiment.

In the present embodiment, the drug particles 16 are coupled to the coating layer 15 by a second catechograph 18.

The drug particle 16 is a PH-dependent drug, and is released to the affected area 30 only at a predetermined PH concentration.

The second PH concentration at which the drug particles 16 are separated from the second catecholator 18 is lower than the first PH concentration at which the exothermic nanoparticles 13 are separated from the first catecholator 17 .

Thereby, after the heat-generating nanoparticles 13 are firstly separated from the membrane 12 under the first PH concentration, the drug particles 16 are separated from the heat-generating nanoparticles 13 under a second concentration of the PH 2 And is discharged to the affected area 30.

3 is a block diagram of an extracorporeal field driven type treatment system according to an embodiment of the present invention.

The extracorporeal field-driven therapeutic system of the present invention comprises the above-described stent 10 and the magnetic field generator 20 as shown in Fig.

The stent 10 is inserted into the body and has the above-described structure.

The magnetic field generator 20 is composed of electromagnetic coils of three or more axes and is disposed outside the body to generate a magnetic field.

The heat generating nanoparticles 13 inserted into the body by the magnetic field generated by the magnetic field generator 20 generate heat and move.

Hereinafter, a manufacturing method and an operation process of the present invention having the above-described configuration will be described.

FIGS. 4 to 6 are flowcharts illustrating a process of drug release by the extracorporeal field-driven therapeutic system according to an embodiment of the present invention.

The stent 10 in which the membrane 12 is formed is inserted into the annular portion 30 where cancer cells or the like exist as shown in FIG.

4, the heat generating nanoparticles 13 and the drug particles 16 are introduced into the membrane 12 by the first and second catechographs 17 and 18, ).

Generally, since cancer cells have acidity, when the membrane 12 comes into contact with the affected part 30 such as a cancer cell, if the PH concentration reaches a predetermined first PH concentration (about PH6), the first catheter (17) is cut.

As shown in FIG. 5, the heat generating nanoparticles 13 to which the drug particles 16 are bound can be separated and moved and rotated by the cutting of the first catheter 17, do.

In this state, when the magnetic field generator 20 disposed outside the body is operated, the heat generating nanoparticles 13 generate heat and are moved to the affected part 30 by the operation of the magnetic field generator 20, So that the affected part 30 can be thermally treated.

Further, as the exothermic nanoparticles 13 connected to the second catecholator 18 are moved to the ring portion 30, the PH concentration becomes lower and the second PH concentration PH4 to 5), the second cater unit 18 is disconnected.

As shown in FIG. 6, the drug particles 16 are separated from the heat generating nanoparticles 13 by the cutting of the second catechol 18, and are released to the affected part 30.

At this time, since the drug particle 16 is a PH-dependent drug, the drug particle 16 is locally released to the affected area 30 at a predetermined specific PH concentration, so that the therapeutic effect can be enhanced.

As described above, the present invention is a noninvasive type, and it is possible to simultaneously operate the stent 10-based heat treatment and the drug treatment in vitro, so that the synergistic effect of cancer treatment can be obtained and there is no exposure such as radioactivity.

In addition, since only the cancer cells targeted at a specific PH concentration are traced to release the drug, the cancer treatment can be accurately performed.

In addition, since the movement of the exoergic nanoparticles 13 in the body can be controlled by using the local magnetic field generated by the magnetic field generator 20, a nanobot can be realized that targets and kills cancer cells while retaining normal cells .

The stent having the drug release and heat treatment function of the present invention and the extracorporeal field driven type therapeutic system using the same are not limited to the above embodiments and can be variously modified within the scope of the technical idea of the present invention.

The present invention relates to a stent for stent delivery in which a stent is introduced into a body part of a stent body,
20: magnetic field generator,
30: lesion (cancer cell)

Claims (12)

A body portion made of wire;
And a membrane formed by coating nanofibers on the body portion,
Wherein the membrane is connected to the heat generating nanoparticles and the drug particles. The method according to claim 1,
Wherein the heat generating nanoparticles generate heat by a magnetic field. The method of claim 2,
Wherein the exothermic nanoparticles comprise iron oxide nanoparticles. ≪ RTI ID = 0.0 > 15. < / RTI > The method of claim 3,
The heat-generating nanoparticles may be prepared,
Iron oxide nanoparticles;
And a coating layer coated on the surface of the iron oxide nanoparticles,
Wherein the exothermic nanoparticles are bound to the membrane by a first catecholizer. ≪ RTI ID = 0.0 > 15. < / RTI > The method of claim 4,
Wherein the exothermic nanoparticles are moved by a magnetic field externally applied. The method of claim 5,
Wherein the drug particles are bound to the coating layer by a second catecholizing agent. The method of claim 6,
The drug particles are released into the affected area only at a predetermined specific PH concentration,
Wherein the second PH concentration at which the drug particles are separated from the second catecholater is lower than the first PH concentration at which the exothermic nanoparticles are separated in the first catecholer so that the exothermic nanoparticles undergo first- Wherein the drug particles are secondarily separated from the exoergic nanoparticles and released to the affected part under a lower second PH concentration. A stent inserted into the body;
And a magnetic field generator disposed outside the body to generate a magnetic field,
In the stent,
A body portion made of wire;
And a membrane formed by coating nanofibers on the body portion,
The heat-generating nanoparticles and drug particles are connected to the membrane,
Wherein the exothermic nanoparticles generate heat by a magnetic field generated by the magnetic field generator. The method of claim 8,
Wherein the heat generating nanoparticles comprise iron oxide nanoparticles. The method of claim 8,
Wherein the exothermic nanoparticles are bound to the membrane by a first catechol,
Said drug particles being bound to said exothermic nanoparticles by a second catechol,
Wherein the exothermic nanoparticles are moved to the affected part together with the drug particles when the exothermic nanoparticles are separated from the first cate- goler. The method of claim 10,
Wherein the exothermic nanoparticles are moved together with the drug particles by a magnetic field externally applied. The method of claim 10,
The drug particles are released into the affected area only at a predetermined specific PH concentration,
Wherein the second PH concentration at which the drug particles are separated from the second catecholater is lower than the first PH concentration at which the exothermic nanoparticles are separated in the first catecholer so that the exothermic nanoparticles undergo first- Wherein the drug particles are secondarily separated from the exoergic nanoparticles and released to the affected part under a lower second PH concentration.
KR1020150178750A 2015-12-15 2015-12-15 Stent having drug release and heat treatment functions and electromagnetic field-driven treatment system using the same KR101777194B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150178750A KR101777194B1 (en) 2015-12-15 2015-12-15 Stent having drug release and heat treatment functions and electromagnetic field-driven treatment system using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150178750A KR101777194B1 (en) 2015-12-15 2015-12-15 Stent having drug release and heat treatment functions and electromagnetic field-driven treatment system using the same

Publications (2)

Publication Number Publication Date
KR20170070978A true KR20170070978A (en) 2017-06-23
KR101777194B1 KR101777194B1 (en) 2017-09-11

Family

ID=59283669

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150178750A KR101777194B1 (en) 2015-12-15 2015-12-15 Stent having drug release and heat treatment functions and electromagnetic field-driven treatment system using the same

Country Status (1)

Country Link
KR (1) KR101777194B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190063245A (en) 2017-11-29 2019-06-07 전북대학교산학협력단 Breast cancer treatment and breast reconstruction device using nano-fiber
CN113143843A (en) * 2021-03-15 2021-07-23 上海交通大学 Medical nano-particle fixed-point treatment device and manufacturing method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101212990A (en) * 2005-07-01 2008-07-02 金文申有限公司 Medical devices comprising a reticulated composite material
KR100883329B1 (en) 2007-08-21 2009-02-11 주식회사 에스앤지바이오텍 Drug releasing membrane for stent and drug releasing stent for expending intra luminal comprising the same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190063245A (en) 2017-11-29 2019-06-07 전북대학교산학협력단 Breast cancer treatment and breast reconstruction device using nano-fiber
CN113143843A (en) * 2021-03-15 2021-07-23 上海交通大学 Medical nano-particle fixed-point treatment device and manufacturing method thereof
CN113143843B (en) * 2021-03-15 2023-11-28 上海交通大学 Medical nanoparticle fixed-point treatment device and manufacturing method thereof

Also Published As

Publication number Publication date
KR101777194B1 (en) 2017-09-11

Similar Documents

Publication Publication Date Title
Rajendrakumar et al. Nanoparticle-based phototriggered cancer immunotherapy and its domino effect in the tumor microenvironment
Das et al. Boosted hyperthermia therapy by combined AC magnetic and photothermal exposures in Ag/Fe3O4 nanoflowers
Brazel Magnetothermally-responsive nanomaterials: combining magnetic nanostructures and thermally-sensitive polymers for triggered drug release
US11260128B2 (en) Synergistic nanotherapy systems and methods of use thereof
CN1217219A (en) Improved targeted hysteresis hyperthermia as method for treating diseased tissue
US20100106181A1 (en) In-situ filter
CA2701628A1 (en) A photonic based non-invasive surgery system that includes automated cell control and eradication via pre-calculated feed-forward control plus image feedback control for targeted energy delivery
US20170224822A1 (en) Methods for killing cancer cells and cellular imaging using magneto-electric nano-particles and external magnetic field
Munaweera et al. Radiotherapeutic bandage based on electrospun polyacrylonitrile containing holmium-166 iron garnet nanoparticles for the treatment of skin cancer
KR101777194B1 (en) Stent having drug release and heat treatment functions and electromagnetic field-driven treatment system using the same
US11643644B2 (en) Methods and devices for simultaneous optical irradiation and oscillating magnetic field radiation of a target
JP2020527545A5 (en)
Grillone et al. Magnetic nanotransducers in biomedicine
Shakeri-Zadeh et al. Targeted, Monitored, and Controlled Chemotherapy: A Multimodal Nanotechnology‐Based Approach against Cancer
US20150157872A1 (en) Device for Treating Cancer by Hyperthermia and the Method Thereof
JP6313705B2 (en) Ultrasound-mediated delivery with critical organ protection
JP6376979B2 (en) Method for synthesizing nanocarriers comprising radiation-sensitive copolymers as constituents
Fymat Nanooncology: Perspective on promising anti-tumor therapies
TWI722061B (en) Ion implantation of magnetic elements into nanodiamond particles to form composition for medical usage
West et al. Plasmonic Magnesium Nanoparticles Are Efficient Nanoheaters
Mukherjee et al. Inorganic Nanoparticles in Anti-angiogenic Cancer Therapy
JP2016185945A (en) Protein and antibody
Hoang et al. The potential for metal nanoparticle-enhanced radiotherapy in dermatology
Thorat et al. Introduction to external field stimulation modalities
TWI423820B (en) Drug carrier

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant